SEPARATION AGREEMENTSeparation Agreement • August 28th, 2017 • Synlogic, Inc. • Pharmaceutical preparations • Texas
This Separation Agreement (the “Agreement”) by and between Paul Lammers (“Executive”) and Mirna Therapeutics, Inc., a Delaware corporation (the “Company”), is made effective eight (8) days after Executive’s signature hereto (the “Effective Date”), unless Executive revokes his acceptance of this Agreement as provided in Section 5(c) below, with reference to the following facts:
CONFIDENTIAL TREATMENT REQUESTED AGREEMENT AND PLAN OF MERGER BY AND AMONG ABBVIE S.À.R.L. SUFFOLK MERGER SUB, INC. SYNLOGIC IBDCO, INC. SYNLOGIC, LLC SYNLOGIC, INC. AND THE FOUNDERS DATED AS OF JULY 16, 2015Confidential Treatment Requested • August 28th, 2017 • Synlogic, Inc. • Pharmaceutical preparations • Delaware
This Agreement and Plan of Merger (this “Agreement”) dated as of July 16, 2015 (the “Execution Date”), by and among AbbVie S.à.r.l., a corporation organized under the laws of Luxembourg (“Buyer”), Suffolk Merger Sub, Inc. a Delaware corporation (“Merger Sub”), Synlogic IBDCo, Inc., a Delaware corporation (the “Company”), Synlogic, LLC, a Delaware corporation (the “Parent”), Synlogic, Inc., a wholly-owned subsidiary of the Parent (“Synlogic”), and (solely for purposes of Section 7.13 hereof) each of the Founders.
MASSACHUSETTS INSTITUTE OF TECHNOLOGY SYNLOGIC, INC. EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • August 28th, 2017 • Synlogic, Inc. • Pharmaceutical preparations • Massachusetts
This Agreement, effective as of November 9, 2015 (the “EFFECTIVE DATE”), is between the Massachusetts Institute of Technology (“M.I.T.”), a Massachusetts non-profit corporation, with a principal office at 77 Massachusetts Avenue, Cambridge, MA 02139-4307 and Synlogic, Inc. (“COMPANY”), a corporation with a principal place of business at 130 Brookline Street, #201, Cambridge, MA 02139. Individually, M.I.T. and COMPANY are a “Party” and collectively, M.I.T. and COMPANY are the “Parties”.
Synlogic, Inc.Letter Agreement • August 28th, 2017 • Synlogic, Inc. • Pharmaceutical preparations • Massachusetts
Synlogic, Inc.Synlogic, Inc. • August 28th, 2017 • Pharmaceutical preparations
This letter confirms our earlier discussions and memorializes the decision approved by the Board of Directors of Synlogic, Inc. (the “Company”) to amend certain provisions of your employment offer letter, effective as of June 22, 2016, and amended as of November 7, 2016, by and between you and the Company (the “Letter Agreement”). The following amendment to the Letter Agreement will be effective as of May 16, 2017.
Synlogic, Inc.Synlogic, Inc. • August 28th, 2017 • Pharmaceutical preparations
This letter confirms our earlier discussions and memorializes the decision approved by the Board of Directors of Synlogic, Inc. (the “Company”) to amend certain provisions of your employment offer letter, effective as of March 20, 2015, by and between you and the Company (the “Letter Agreement”). The following amendment to the Letter Agreement will be effective as of May 16, 2017.
CONFIDENTIAL TREATMENT REQUESTED Boston University Massachusetts Institute of Technology Synlogic, Inc. License Agreement Effective as of October 18, 2015Equity Agreement • August 28th, 2017 • Synlogic, Inc. • Pharmaceutical preparations • Massachusetts
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
LICENSE AGREEMENT BY AND BETWEEN SYNLOGIC, INC. AND SYNLOGIC IBDCO, INC.License Agreement • August 28th, 2017 • Synlogic, Inc. • Pharmaceutical preparations • Delaware
This License Agreement (the “Agreement”) is made and effective as of the 16th day of July, 2015 (the “Effective Date”) by and between Synlogic, Inc., a Delaware corporation, with offices at 130 Brookline Street, Suite 201, Cambridge, MA 20139 (“Synlogic”) and Synlogic IBDCo, Inc., a Delaware corporation, with offices at 130 Brookline Street, Suite 201, Cambridge, MA 20139 (“Company”).
Synlogic, Inc. Cambridge, MA 02139 FIRST AMENDMENT TO OFFER LETTEROffer Letter • August 28th, 2017 • Synlogic, Inc. • Pharmaceutical preparations
This FIRST AMENDMENT TO OFFER LETTER (this “First Amendment”), amending the Offer Letter dated June 22, 2016 (the “Offer Letter”), by and between SYNLOGIC, (the “Company”), and DR. AOIFE BRENNAN (“Employee”), is entered into as of November 7, 2016 by and between the Company and the Employee. Capitalized terms used herein which are not defined herein shall have the definition ascribed to in the Offer Letter.
